Iadademstat with Azacitidine for Myelodysplastic Syndromes
This study is testing a new combination treatment for adults with Myelodysplastic Syndromes (MDS), a type of blood cancer. Researchers are combining a drug called iadademstat with azacitidine, a standard treatment. The main goal is to find the safest and most effective dose of iadademstat when given with azacitidine. You might be able to join if you are 18 or older, have been diagnosed with MDS (or related conditions like MDS/MPN or CMML), and your condition is considered intermediate, high, or very-high risk. The study is currently unclear on its recruitment status and plans to enroll 12 participants.
- Study design
- This is a single-arm, open-label Phase 1 study with a dose-escalation design, meaning all participants receive the study drugs and everyone knows which drugs are being given. It will enroll a small number of participants, around 12.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, determining the recommended dose, will be measured for up to two years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Guru Subramanian Guru Murthy, MD, MS · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Recommended phase II dose of Iadademstat.Up to two years
The dose identified in this trial that will be used in future clinical trials.